Subsidiary of Zhejiang Jiuzhou Pharmaceutical (603456.SH) plans to participate in the investment of Jiaxing Longfeng Entrepreneurship Investment Partnership (Limited Partnership)

Zhejiang Jiuzhou Pharmaceutical (603456.SH) announced that its wholly-owned subsidiary, Hongzhou Investment, plans to participate in the investment of Jiaxing Longfeng Entrepreneurial Investment Partnership Enterprise (Limited Partnership). The total subscribed capital of the partnership enterprise is 77 million yuan (including this investment), and Hongzhou Investment will subscribe for 10 million yuan as a limited partner with its own funds, accounting for 12.987% of the total subscribed capital of the partnership enterprise. The investment direction of the partnership enterprise is mainly in the pharmaceutical field, including new drug research and development, medical device research projects, and other pharmaceutical-related areas. It mainly focuses on high-quality emerging medical companies, including but not limited to new drugs, innovative drugs, medical devices, medical services, diagnostics, biotechnology, and pharmaceutical outsourcing research and development enterprises.